Prof. Ömür Gökmen Sevindik, M.D.

2022
International Medical School of Medipol University
Chief of Internal Medicine

2018
Turkish Society of Hematology
Chair of Multiple Myeloma Scientific Subcommittee

2018
Medipol Istanbul University Minimally Invasive & Robotic
Prof., Department of Hematology & BMT

2014-2015
Mayo Clinic, Rochester MN, US
Visiting Clinician – Division of Hematology

2011
Dokuz Eylul University, Graduate  School of Medicine
Fellowship – Hematology

2005-2010
Dokuz Eylul University, Graduate School of Medicine
Clinical Residency – Internal Medicine

1998-2005
Hacettepe University, School of Medicine
Medical School & Internship

• Hematological Malignancies
• Stem Cell Transplantation

1. ADIYAMAN S, ALACACIOĞLU İ, Danyeli A, Turkyilmaz D, Sevindik O, Demirkan F, et al. Prognostic factors in elderly patients with diffuse large B-cell lymphoma and their treatment results. Turkish Journal of Hematology. 2019;36(2).
2. Akkus E, Tuncalı T, Akın HY, Aydın Y, Beşışık SK, Gürkan E, et al. Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases. British Journal of Haematology. 2024;204(3):931-8.
3. Aksoy A, Artas G, Sevindik OG. Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer. Pakistan journal of medical sciences. 2017;33(3):560.
4. Alacacioglu I, Medeni SS, Ozsan GH, Payzin B, Sevindik OG, Acar C, et al. Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers. Chemotherapy. 2015;60(4):219-23.
5. Alacacioglu I, Turkyilmaz D, Medeni SS, Acar C, Sevindik O, Piskin O, et al., editors. Does reinfusion of stem cell products in multiple days affect engraftment? BONE MARROW TRANSPLANTATION; 2015: NATURE PUBLISHING GROUP MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.
6. Askin AE, Bektas S, Serin I, Mutlu YG, Aydin BB, Sevindik OG. Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia. Indian Journal of Hematology and Blood Transfusion. 2024:1-4.
7. Atas U, Karakus V, Tekin IB, Aydin O, Sevindik OG, Undar L. Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma. International Journal of Laboratory Hematology. 2024.
8. Aykaş F, Karakuş V, Sevindik ÖG. Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction. Clinical Lymphoma, Myeloma & Leukemia. 2022.
9. Aykaş F, Karakuş V, Sevindik ÖG. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction. Journal of Oncology Pharmacy Practice. 2024;30(2):397-9.
10. Balık Aydın B, Mutlu YG, Sevindik ÖG. Persistent polyclonal B-Cell lymphocytosis with binucleated lymphocytes. Turkish Journal of Hematology. 2021.
11. Beköz HS, Sevindik ÖG, Özçelik T, Arat M, Hindilerden IY, Beşışık SK, et al., editors. Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation. 45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT); 2019: Nature Publishing Group.
12. Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network Study (EMN19). Blood. 2022;140(Supplement 1):10177-9.
13. Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19). HemaSphere. 2023;7(S3):e994593a.
14. Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19). Blood. 2023;142:1956.
15. Beksac M, Tuglular T, Unal A, Cavo M, Gay F, Katodritou E, et al. Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. Blood. 2021;138:1657.
16. Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, et al. Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data. Hematological oncology. 2023;41(4):663-73.
17. Borazan A, Sevindik OG, Solmaz D, Gulcu A, Cavdar C, Sifil A, et al. A rare cause of renovascular hypertension: Takayasu arteritis with only renal artery involvement. Renal failure. 2009;31(4):327-31.
18. Bozdag S, Seval G, Hindilerden I, Hindilerden F, Andic N, Baydar M, et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients. 2022.
19. Chatzikonstantinou T, Scarfo L, Demosthenous C, Kotaskova J, Iacoboni G, Minga E, et al. Real-world evidence on therapeutic strategies and treatment-sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. Blood. 2021;138(Supplement 1):2635-.
20. Ciftciler R, Sevindik O, Tekgunduz A, Erkurt M, Vural F, Turgut B, et al. Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter. 2019.